A Comparative Analysis of Serum Lipids in Patients with Chronic Hepatitis C, Nonalcoholic Fatty Liver Disease and Healthy Controls

1. Lonardo A, Adinolfi LE, Loria P et al. Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease. – Gastroenterology 2004, 126, 586-597.10.1053/j.gastro.2003.11.02014762795Search in Google Scholar

2. Loria P, Marchesini G, Nascimbeni F et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. – Atherosclerosis. 232, 2014, 1, 99-109.10.1016/j.atherosclerosis.2013.10.03024401223Search in Google Scholar

3. Adinolfi LE, Rinaldi L, Guerrera B et al. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. – Int J Mol Sci., 2016, 17(6).10.3390/ijms17060803492633727231906Search in Google Scholar

4. Lonardo A, Adinolfi LE, Restivo L et al. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol. 20, 2014, 23:7089-103.10.3748/wjg.v20.i23.7089406405724966582Search in Google Scholar

5. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? – Gut. 2006; 55(1):123-30.10.1136/gut.2005.069757185639516344578Search in Google Scholar

6. Adinolfi LE, Restivo L, Zampino R et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. – Atherosclerosis.221, 2012, 2, 496-502.10.1016/j.atherosclerosis.2012.01.05122385985Search in Google Scholar

7. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Nonalcoholic fatty liver disease: a new and important cardiovascular risk factor? – Eur Heart J. 33, 2012, 10, 1190-2000.10.1093/eurheartj/ehr45322408036Search in Google Scholar

8. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med, 363, 2010, 14, 1341-50.10.1056/NEJMra091206320879883Search in Google Scholar

9. Defilippis AP, Blaha MJ, Martin SS, et al. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 227, 2013, 2, 429-36.10.1016/j.atherosclerosis.2013.01.022404907823419204Search in Google Scholar

10. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014; 60(2):392-420.10.1016/j.jhep.2013.11.00324331294Search in Google Scholar

11. EASL (European Association for the Study of the Liver) – EASD (European Association for the Study of Diabetes) – EASO (European Association for the Study of Obesity) Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6):1388-402.10.1016/j.jhep.2015.11.00427062661Search in Google Scholar

12. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 23, 2006, 5, 469-80.10.1111/j.1464-5491.2006.01858.x16681555Search in Google Scholar

13. WHO/IDF Report, Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia, 2006.Search in Google Scholar

14. Vanni E, Abate ML, Rizzetto M et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology. 2009 Sep;50(3):697-706.10.1002/hep.2303119582803Search in Google Scholar

15. Jonsson JR, Barrie HD, O’Rourke P et al. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 48, 2008, 1, 80-87.10.1002/hep.2231118571785Search in Google Scholar

16. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 49, 2008, 5, 831-44.10.1016/j.jhep.2008.08.006264297118814931Search in Google Scholar

17. Siagris D, Christofidou M, Theocharis GJ et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat. 13, 2006, 1, 56-61.10.1111/j.1365-2893.2005.00655.x16364083Search in Google Scholar

18. Hsu CS, Liu CJ, Liu CH et al. Metabolic profiles in patients with chronic hepatitis C: a case-control study. – Hepatol Int. 2, 2008, 2, 250-7.10.1007/s12072-008-9064-3271684619669312Search in Google Scholar

19. Blaising J, Pécheur EI. Lipids: a key for hepatitis C virus entry and a potential target for antiviral strategies. Biochimie 95, 2013; 1, 96-102.10.1016/j.biochi.2012.07.01622884392Search in Google Scholar

20. Syed GH, Tang H, Khan M et al. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J Virol. 88, 2014, 5, 2519-29.10.1128/JVI.02727-13395805024352472Search in Google Scholar

21. Clark PJ, Thompson AJ, Vock DM et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology 56, 2012, 1, 49-56.10.1002/hep.2563122318926Search in Google Scholar

22. Bedossa P, Moucari R, Chelbi E et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology. 46, 2007, 2, 380-7.10.1002/hep.21711Search in Google Scholar

23. Ramcharran D, Wahed AS, Conjeevaram HS et al. Serum lipids and their associations with viral levels and liver disease severity in a treatment-naïve chronic hepatitis C type 1-infected cohort. J Viral Hepat. 18, 2011, 4, e144-52.10.1111/j.1365-2893.2010.01394.xSearch in Google Scholar

24. Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol. 24, 2004, 12, 2219–26.10.1161/01.ATV.0000144010.55563.63Search in Google Scholar

25. Børge G. Nordestgaard BG, Chapman MJ et al. And for the European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 31, 2010, 23, 2844-2853.10.1093/eurheartj/ehq386Search in Google Scholar

26. Ohira T, Schreiner PJ, Morrisett JD, et al. Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 37, 2006, 6, 1407-12.10.1161/01.STR.0000222666.21482.b6Search in Google Scholar

27. Yang MH, Son HJ, Sung JD et al. The relationship between apolipoprotein E polymorphism, lipoprotein (a) and fatty liver disease. Hepato-gastroenterology 52, 2005, 66, 1832-1835.Search in Google Scholar

28. Bozbaş H. et al. Increased lipoprotein(a) in metabolic syndrome: is it a contributing factor to premature atherosclerosis? Anadolu Kardiyol Derg. 8, 2008, 2, 111-5.Search in Google Scholar

29. Malaguarnera M, Giugno I, Trovato BA et al. Lipoprotein(a) concentration in patients with chronic active hepatitis C before and after interferon treatment. Clin Ther. 17, 1995, 4, 721-8.10.1016/0149-2918(95)80048-4Search in Google Scholar

30. Irshad M. Serum lipoprotein (a) levels in liver diseases caused by hepatitis. Indian J Med Res. 120, 2004, 6:542-5.Search in Google Scholar